SAN ANTONIO — Promising data don’t always equal a stock pop. Viking Therapeutics presented what analysts thought were compelling data on an oral … ...
Getty Images Viking Therapeutics shares fell Monday after reporting the latest results from trials of its weight-loss drugs. Analysts say the treatment, which is being tested in both oral and ...
Viking Therapeutics is rowing its longboat toward the front of the oral obesity therapy race, posting detailed phase 1 data that suggest its dual agonist of GLP-1 and GIP can hold its own in a ...
SAN ANTONIO — Viking Therapeutics’ highly anticipated readout of its oral anti-obesity pill showed a placebo-adjusted weight loss of 6.8% after four weeks ...
Viking’s results provided the latest showcase of how much Wegovy and Zepbound’s market success has heightened investor attention on preliminary findings from small studies. The data are from a Phase 1 ...
Viking Therapeutics (VKTX) shares are taking a dive in Monday's session despite on rising manufacturing concerns and competition between pharmaceutical rivals in the GLP-1 weight-loss drug space.
In its latest study, Viking Therapeutics (VKTX) has found promising early results in a trial for its GLP-1 weight-loss drug. Morgan Stanley upgraded Roblox (RBLX) to Overweight and raised its ...
Please Note: All times UK. Tables are subject to change. The BBC is not responsible for any changes that may be made. Manager: Morten Jensen Formation: 4 - 1 - 4 - 1 Manager: Hans Erik Ødegaard ...